Bronfman drops Paramount bid, Eli Lilly lowers weightloss drug price: Yahoo Finance
The saga for Paramount Global (PARA) seems to be nearing an end. Edgar Bronfman Jr. has abandoned his bid for the studio, clearing the path for Skydance Media's deal for the company. Meanwhile, Eli Lilly (LLY) has significantly dropped the price of its weight drug, Zepbound. The company will sell its lowest dose for $399, and its 5 mg dose at $549 for a one-month supply. That's a massive decrease from the current $1,059 price tag. Yahoo Finance trending tickers include PDD Holdings (PDD), The Coca-Cola Company (KO), and Cava Group (CAVA).9:10 a.m. ET Ryan Wang, HSBC Chief US Economist
9:30 a.m. ET Seema Shah, Principal Asset Management Chief Global Strategist10:05 a.m. ET Troy Gayeski, FS Investments Chief Market Strategist10:30 a.m. ET Rishi Jaluria, Managing Director, Software Equity Research at RBC Capital11:30 a.m. ET Ankur Jain, Bilt Rewards Founder & CEO
